10 research outputs found
CYCLODEXTRINS - FIELFS OF APPLICATION. PART II
This paper represents an analysis of potential and current applications of cyclodextrins as biologically
active substances in medicine. The main applications described here include use of cyclodextrins as agents that form
inclusion complexes with endogenous substances (membrane lipids, cellular cholesterol), agents that form inclusion
complexes with exogenous substances with their man role as guest molecules (sugammadex, FBCx), agents that
block endogenous and exogenous macromolecules (ion channels, anthrax toxin, α-hemolysin), and agents which
activity is based on the chemical nature of them and of their derivatives (cyclodextrin polysulphate derivatives). The
fi rst classifi cation for medically important biological activity of cyclodextrins has been proposed
New copper(II) complexes with isoconazole: Synthesis, structures and biological properties
There is an increasing demand for novel metal-based complexes with biologically relevant molecules in technology and medicine. Three new Cu(II) coordination compounds with antifungal agent isoconazole (L), namely mononuclear complexes CuCl2(L)(2) (1), and Cu(O2CMe)(2)(L)(2)center dot 2H(2)O (2) and coordination polymer Cu(pht)(L)(2)(n) (3) (where H(2)pht - o-phthalic acid) were synthesized and characterized by IR spectroscopy, thermogravimetric analysis and X-ray crystallography. X-ray analysis showed that in all complexes, the isoconazole is coordinated to Cu(II) centres by a N atom of the imidazole fragment. In complex I, the square-planar environment of Cu(II) atoms is completed by two N atoms of isoconazole and two chloride ligands, whereas the Cu(II) atoms are coordinated by two N atoms from two isoconazole ligands and two O atoms from the different carboxylate residues: acetate in 2 and phthalate in 3. The formation of an infinite chain through the bridging phthalate ligand is observed in 3. The biosynthetic ability of micromycetes Aspergillus niger CNMN FD 10 in the presence of the prepared complexes 1-3 as well as the antifungal drug isoconazole were studied. Complexes 2 and 3 accelerate the biosynthesis of enzymes (beta-glucosidase, xylanase and endoglucanase) by this fungus. Moreover, a simplified and improved method for the preparation of isoconazole nitrate was developed
Therapeutic treatment of Zika virus infection using a brain-penetrating antiviral peptide
Zika virus is a mosquito-borne virus that is associated with neurodegenerative diseases, including Guillain-Barre syndrome' and congenital Zika syndrome(2). As Zika virus targets the nervous system, there is an urgent need to develop therapeutic strategies that inhibit Zika virus infection in the brain. Here, we have engineered a brain-penetrating peptide that works against Zika virus and other mosquito-borne viruses. We evaluated the therapeutic efficacy of the peptide in a lethal Zika virus mouse model exhibiting systemic and brain infection. Therapeutic treatment protected against mortality and markedly reduced clinical symptoms, viral loads and neuroinflammation, as well as mitigated microgliosis, neurodegeneration and brain damage. In addition to controlling systemic infection, the peptide crossed the blood-brain barrier to reduce viral loads in the brain and protected against Zikavirus-induced blood-brain barrier injury. Our findings demonstrate how engineering strategies can be applied to develop peptide therapeutics and support the potential of a brain-penetrating peptide to treat neurotropic viral infections